FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2612274638> ?p ?o ?g. }

• W2612274638 endingPage "PR01" @default.
• W2612274638 startingPage "PR01" @default.
• W2612274638 abstract "Abstract Tumor cells normally depend on both glycolysis and oxidative phosphorylation (OXPHOS) to provide the energy and macromolecule building blocks needed to enable continued tumor cell growth. Genetic or epigenetic inactivation of one of these two redundant pathways represents a metabolic vulnerability that should be susceptible to an inhibitor of the other pathway. We have identified multiple contexts where all or a subset of these tumors demonstrate a dependence on mitochondrial OXPHOS, which represents an exciting therapeutic opportunity. Through an extensive medicinal chemistry campaign, IACS-10759 was identified as a potent inhibitor of complex I of oxidative phosphorylation. In isolated mitochondria or permeabilized cells, ATP production or oxygen consumption is inhibited at single digit nM concentrations in the presence of malate/glutamate, but not succinate. More directly, IACS-10759 inhibits the conversion of NADH to NAD+ in an immunoprecipitated complex I assay at low nM concentrations. Importantly, IACS-10759 is orally bioavailable with excellent pharmacokinetics properties in preclinical species, and has an overall profile suitable for clinical development. Our group and others have demonstrated that a variety of tumor types including: AML, plus subsets of lymphoma, breast, melanoma and PDAC are highly dependent on OXPHOS to meet energy and biomass demands. Treatment of multiple cell lines and patient derived xenograft (PDX) models in multiple cancer types with IACS-10759 led to decreased oxygen consumption rate (OCR). IACS-10759 treatment also led to a robust decrease in cell viability and often an increase in apoptosis with EC50 values between 1 nM - 50 nM across multiple lines. In multiple PDX models of primary AML IACS-10759 treatment extends the median survival. Efficacy was paralleled by robust modulation of OCR, aspartate, and p-AMPK levels. Additionally, tumor growth inhibition or regression was also observed in cell line and PDX xenograft models of lymphoma, triple negative breast, melanoma and PDAC treated with IACS-10759, indicating that subsets of several non-AML indications are also dependent on OXPHOS. Mechanistically, extensive metabolic profiling revealed that the response to IACS-10759 was associated with induction of a metabolic imbalances that negatively impacted energy homeostasis, amino acid biosynthesis, and NTP production due to reduced conversion of NADH to NAD+ by complex I, decreased ATP production, TCA cycle flux and nucleotide biosynthesis. As a result of the robust preclinical response in multiple model systems, IACS-10759 has been advanced through IND enabling studies. GLP safety and toxicology have been completed, clinical supplies manufactured, and a Phase I clinical trial in AML will be initiated during the second quarter of 2016. This abstract is also being presented as Poster B35. Citation Format: Philip Jones, M Emilia Di Francesco, Jennifer M. Molina, Marina Protopopova, Madhavi Bandi, Jennifer Bardenhagen, Christopher A. Bristow, Christopher L. Carroll, Ningping Feng, Jason P. Gay, Mary K. Geck Do, Jennifer M. Greer, Marina Konopleva, Zhijun Kang, Gang Liu, Timothy McAfoos, Pietro Morlacchi, Melinda G. Smith, Sonal Fnu, Jay P. Theroff, Giulio Draetta, Giulio Draetta, Carlo Toniatti, Joseph R. Marszalek. IACS-010759 a novel inhibitor of oxidative phosphorylation advancing into first-in-human studies to exploit metabolic vulnerabilities. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer; May 16-19, 2016; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(1_Suppl):Abstract nr PR01." @default.
• W2612274638 created "2017-05-19" @default.
• W2612274638 creator A5000082629 @default.
• W2612274638 creator A5000496523 @default.
• W2612274638 creator A5008178231 @default.
• W2612274638 creator A5009873142 @default.
• W2612274638 creator A5012999075 @default.
• W2612274638 creator A5015441971 @default.
• W2612274638 creator A5019124766 @default.
• W2612274638 creator A5022647201 @default.
• W2612274638 creator A5027912927 @default.
• W2612274638 creator A5037541103 @default.
• W2612274638 creator A5039617494 @default.
• W2612274638 creator A5040531332 @default.
• W2612274638 creator A5045486522 @default.
• W2612274638 creator A5048521277 @default.
• W2612274638 creator A5053772599 @default.
• W2612274638 creator A5057441629 @default.
• W2612274638 creator A5058637832 @default.
• W2612274638 creator A5060702881 @default.
• W2612274638 creator A5067485402 @default.
• W2612274638 creator A5071445059 @default.
• W2612274638 creator A5081217745 @default.
• W2612274638 creator A5089004171 @default.
• W2612274638 date "2017-01-01" @default.
• W2612274638 modified "2023-09-30" @default.
• W2612274638 title "Abstract PR01: IACS-010759 a novel inhibitor of oxidative phosphorylation advancing into first-in-human studies to exploit metabolic vulnerabilities" @default.
• W2612274638 doi "https://doi.org/10.1158/1557-3265.pmccavuln16-pr01" @default.
• W2612274638 hasPublicationYear "2017" @default.
• W2612274638 type Work @default.
• W2612274638 sameAs 2612274638 @default.
• W2612274638 citedByCount "1" @default.
• W2612274638 countsByYear W26122746382018 @default.
• W2612274638 crossrefType "journal-article" @default.
• W2612274638 hasAuthorship W2612274638A5000082629 @default.
• W2612274638 hasAuthorship W2612274638A5000496523 @default.
• W2612274638 hasAuthorship W2612274638A5008178231 @default.
• W2612274638 hasAuthorship W2612274638A5009873142 @default.
• W2612274638 hasAuthorship W2612274638A5012999075 @default.
• W2612274638 hasAuthorship W2612274638A5015441971 @default.
• W2612274638 hasAuthorship W2612274638A5019124766 @default.
• W2612274638 hasAuthorship W2612274638A5022647201 @default.
• W2612274638 hasAuthorship W2612274638A5027912927 @default.
• W2612274638 hasAuthorship W2612274638A5037541103 @default.
• W2612274638 hasAuthorship W2612274638A5039617494 @default.
• W2612274638 hasAuthorship W2612274638A5040531332 @default.
• W2612274638 hasAuthorship W2612274638A5045486522 @default.
• W2612274638 hasAuthorship W2612274638A5048521277 @default.
• W2612274638 hasAuthorship W2612274638A5053772599 @default.
• W2612274638 hasAuthorship W2612274638A5057441629 @default.
• W2612274638 hasAuthorship W2612274638A5058637832 @default.
• W2612274638 hasAuthorship W2612274638A5060702881 @default.
• W2612274638 hasAuthorship W2612274638A5067485402 @default.
• W2612274638 hasAuthorship W2612274638A5071445059 @default.
• W2612274638 hasAuthorship W2612274638A5081217745 @default.
• W2612274638 hasAuthorship W2612274638A5089004171 @default.
• W2612274638 hasConcept C121608353 @default.
• W2612274638 hasConcept C1491633281 @default.
• W2612274638 hasConcept C181199279 @default.
• W2612274638 hasConcept C185592680 @default.
• W2612274638 hasConcept C20251656 @default.
• W2612274638 hasConcept C28859421 @default.
• W2612274638 hasConcept C502942594 @default.
• W2612274638 hasConcept C53227056 @default.
• W2612274638 hasConcept C54355233 @default.
• W2612274638 hasConcept C55493867 @default.
• W2612274638 hasConcept C57600042 @default.
• W2612274638 hasConcept C62231903 @default.
• W2612274638 hasConcept C75520062 @default.
• W2612274638 hasConcept C86803240 @default.
• W2612274638 hasConcept C95444343 @default.
• W2612274638 hasConcept C96232424 @default.
• W2612274638 hasConcept C98274493 @default.
• W2612274638 hasConceptScore W2612274638C121608353 @default.
• W2612274638 hasConceptScore W2612274638C1491633281 @default.
• W2612274638 hasConceptScore W2612274638C181199279 @default.
• W2612274638 hasConceptScore W2612274638C185592680 @default.
• W2612274638 hasConceptScore W2612274638C20251656 @default.
• W2612274638 hasConceptScore W2612274638C28859421 @default.
• W2612274638 hasConceptScore W2612274638C502942594 @default.
• W2612274638 hasConceptScore W2612274638C53227056 @default.
• W2612274638 hasConceptScore W2612274638C54355233 @default.
• W2612274638 hasConceptScore W2612274638C55493867 @default.
• W2612274638 hasConceptScore W2612274638C57600042 @default.
• W2612274638 hasConceptScore W2612274638C62231903 @default.
• W2612274638 hasConceptScore W2612274638C75520062 @default.
• W2612274638 hasConceptScore W2612274638C86803240 @default.
• W2612274638 hasConceptScore W2612274638C95444343 @default.
• W2612274638 hasConceptScore W2612274638C96232424 @default.
• W2612274638 hasConceptScore W2612274638C98274493 @default.
• W2612274638 hasIssue "1_Supplement" @default.
• W2612274638 hasLocation W26122746381 @default.
• W2612274638 hasOpenAccess W2612274638 @default.
• W2612274638 hasPrimaryLocation W26122746381 @default.
• W2612274638 hasRelatedWork W1976531907 @default.
• W2612274638 hasRelatedWork W1976564273 @default.
• W2612274638 hasRelatedWork W2045818454 @default.
• W2612274638 hasRelatedWork W2057981436 @default.

• next